<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38540252</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">639</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12030639</ELocationID><Abstract><AbstractText>SARS-CoV-2 infection is a significant health concern that needs to be addressed not only during the initial phase of infection but also after hospitalization. This is the consequence of the various pathologies associated with long COVID-19, which are still being studied and researched. Lung fibrosis is an important complication after COVID-19, found in up to 71% of patients after discharge. Our research is based on scientific articles indexed in PubMed; in the selection process, we used the following keywords: "lung fibrosis", "fibrosis mediators", "fibrosis predictors", "COVID-19", "SARS-CoV-2 infection", and "long COVID-19". In this narrative review, we aimed to discuss the current understanding of the mechanisms of initiation and progression of post-COVID-19 lung fibrosis (PC-19-LF) and the risk factors for its occurrence. The pathogenesis of pulmonary fibrosis involves various mediators such as TGF-&#x3b2;, legumain, osteopontin, IL-4, IL-6, IL-13, IL-17, TNF-&#x3b1;, Gal-1, Gal-3, PDGF, and FGFR-1. The key cellular effectors involved in COVID-19 lung fibrosis are macrophages, epithelial alveolar cells, neutrophils, and fibroblasts. The main fibrosis pathways in SARS-CoV-2 infection include hypoxemia-induced fibrosis, macrophage-induced fibrosis, and viral-fibroblast interaction-induced fibrosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1169-3653</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Infectious Diseases "Prof. Dr. Matei Bals", No. 1, Calistrat Grozovici Street, Sector 2, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandulescu</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6432-0535</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbu</LastName><ForeName>Ecaterina Constanta</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitu-Tisu</LastName><ForeName>Cristina Emilia</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreescu</LastName><ForeName>Darie Ioan</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anton</LastName><ForeName>Andreea Nicoleta</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erculescu</LastName><ForeName>Teodora Maria</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petre</LastName><ForeName>Alexandru Mihai</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duca</LastName><ForeName>George Theodor</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simion</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padiu</LastName><ForeName>Isabela Felicia</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacurar</LastName><ForeName>Cosmina Georgiana</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosca</LastName><ForeName>Ruxandra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simian</LastName><ForeName>Teodor Mihai</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oprea</LastName><ForeName>Constantin Adrian</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ion</LastName><ForeName>Daniela Adriana</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">fibrosis mediators</Keyword><Keyword MajorTopicYN="N">fibrosis predictors</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">lung fibrosis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38540252</ArticleId><ArticleId IdType="pmc">PMC10968428</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12030639</ArticleId><ArticleId IdType="pii">biomedicines12030639</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mineo G., Ciccarese F., Modolon C., Landini M.P., Valentino M., Zompatori M. Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: Role of follow-up CT. Radiol. Med. 2012;117:185&#x2013;200. doi: 10.1007/s11547-011-0740-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11547-011-0740-3</ArticleId><ArticleId IdType="pmc">PMC7102178</ArticleId><ArticleId IdType="pubmed">22020433</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh J.-M., Tseng H.-Y., Jung F., Yang S.-H., Lin J.-C. Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model. Mediat. Inflamm. 2019;2019:7947596. doi: 10.1155/2019/7947596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7947596</ArticleId><ArticleId IdType="pmc">PMC6458868</ArticleId><ArticleId IdType="pubmed">31049028</ArticleId></ArticleIdList></Reference><Reference><Citation>She Y.X., Yu Q.Y., Tang X.X. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7:52. doi: 10.1038/s41420-021-00437-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00437-9</ArticleId><ArticleId IdType="pmc">PMC7960958</ArticleId><ArticleId IdType="pubmed">33723241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaub E.A., Dubey A., Imani J., Botelho F., Kolb M.R.J., Richards C.D., Ask K. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci. Rep. 2017;7:13281. doi: 10.1038/s41598-017-13511-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13511-z</ArticleId><ArticleId IdType="pmc">PMC5643520</ArticleId><ArticleId IdType="pubmed">29038604</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegunsoye A., Balachandran J. Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea. Mediat. Inflamm. 2015;2015:510105. doi: 10.1155/2015/510105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/510105</ArticleId><ArticleId IdType="pmc">PMC4402194</ArticleId><ArticleId IdType="pubmed">25944985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter M., M&#xfc;ller-Ladner U., Costabel U., Jonigk D., Heu&#xdf;el C.P. The Diagnosis and Treatment of Pulmonary Fibrosis. Dtsch. Aerzteblatt Int. 2021;118:152&#x2013;162. doi: 10.3238/arztebl.m2021.0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.m2021.0018</ArticleId><ArticleId IdType="pmc">PMC8212400</ArticleId><ArticleId IdType="pubmed">33531115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Li R., Chen Y., Zhang J., Zheng Y., Xu M., Liang J., Li J., Huang Y., Xu Y., et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: A retrospective study. BMC Infect. Dis. 2022;22:788. doi: 10.1186/s12879-022-07747-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07747-y</ArticleId><ArticleId IdType="pmc">PMC9562065</ArticleId><ArticleId IdType="pubmed">36241980</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Gao J., Wang G., Fei G. Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-&#x3b2;1. Mol. Med. Rep. 2016;14:1297&#x2013;1301. doi: 10.3892/mmr.2016.5366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5366</ArticleId><ArticleId IdType="pubmed">27279470</ArticleId></ArticleIdList></Reference><Reference><Citation>Leader J.K., Crothers K., Huang L., King M.A., Morris A., Thompson B.W., Flores S.C., Drummond M.B.M., Rom W.N., Diaz P.T. Risk Factors Associated with Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort. J. Acquir. Immune Defic. Syndr. 2016;71:420&#x2013;427. doi: 10.1097/QAI.0000000000000894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000000894</ArticleId><ArticleId IdType="pmc">PMC4770858</ArticleId><ArticleId IdType="pubmed">26914911</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J.P., Egan J.J., Ross A.J., Kelly B.G., Lok S.S., Hasleton P.S., Woodcock A.A. The Detection of Epstein-Barr Virus DNA in Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 1999;159:1336&#x2013;1341. doi: 10.1164/ajrccm.159.4.9807077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.159.4.9807077</ArticleId><ArticleId IdType="pubmed">10194186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Bae S., Chang H.-H., Kim S.-W. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci. Rep. 2023;13:11207. doi: 10.1038/s41598-023-36995-4. Erratum in Sci. Rep. 2023, 13, 11960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36995-4</ArticleId><ArticleId IdType="pmc">PMC10336045</ArticleId><ArticleId IdType="pubmed">37433819</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuculeanu G., Barbu E.C., Lazar M., Chitu-Tisu C.E., Moisa E., Negoita S.I., Ion D.A. Coagulation Disorders in Sepsis and COVID-19&#x2014;Two Sides of the Same Coin? A Review of Inflammation&#x2013;Coagulation Crosstalk in Bacterial Sepsis and COVID-19. J. Clin. Med. 2023;12:601. doi: 10.3390/jcm12020601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12020601</ArticleId><ArticleId IdType="pmc">PMC9866352</ArticleId><ArticleId IdType="pubmed">36675530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar M., Barbu E.C., Chitu C.E., Tiliscan C., Stratan L., Arama S.S., Arama V., Ion D.A. Interstitial Lung Fibrosis Following COVID-19 Pneumonia. Diagnostics. 2022;12:2028. doi: 10.3390/diagnostics12082028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12082028</ArticleId><ArticleId IdType="pmc">PMC9407299</ArticleId><ArticleId IdType="pubmed">36010377</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin B.J.H., Kakamad F.H., Ahmed G.S., Ahmed S.F., Abdulla B.A., Mohammed S.H., Mikael T.M., Salih R.Q., Ali R.K., Salh A.M., et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann. Med. Surg. 2022;77:103590. doi: 10.1016/j.amsu.2022.103590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103590</ArticleId><ArticleId IdType="pmc">PMC8983072</ArticleId><ArticleId IdType="pubmed">35411216</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., Hu P., Guo L., Liu M., Xu J., et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D., Dietrich O., Mari T., von Stillfried S., Ibarra I.L., Mittermaier M., Mache C., Chua R.L., Knoll R., Timm S., et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184:6243&#x2013;6261.e27. doi: 10.1016/j.cell.2021.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero F., Shah D., Duong M., Penn R.B., Fessler M.B., Madenspacher J., Stafstrom W., Kavuru M., Lu B., Kallen C.B., et al. A Pneumocyte&#x2013;Macrophage Paracrine Lipid Axis Drives the Lung toward Fibrosis. Am. J. Respir. Cell Mol. Biol. 2015;53:74&#x2013;86. doi: 10.1165/rcmb.2014-0343OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2014-0343OC</ArticleId><ArticleId IdType="pmc">PMC4566113</ArticleId><ArticleId IdType="pubmed">25409201</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulivendala G., Bale S., Godugu C. Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-&#x3b2;/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo. Toxicol. Appl. Pharmacol. 2020;391:114913. doi: 10.1016/j.taap.2020.114913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2020.114913</ArticleId><ArticleId IdType="pubmed">32032644</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama T., Kubli S.P., Yoshinaga S.K., Pfeffer K., Mak T.W. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209&#x2013;3225. doi: 10.1038/s41418-020-00633-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00633-7</ArticleId><ArticleId IdType="pmc">PMC7545020</ArticleId><ArticleId IdType="pubmed">33037393</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranatha D., Hasan H., Bakhtiar A., Widyoningroem A. Aryati Association of TNF-&#x3b1;, TGF-&#x3b2;1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19. J. Infect. Public Health. 2022;15:1072&#x2013;1075. doi: 10.1016/j.jiph.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.08.007</ArticleId><ArticleId IdType="pmc">PMC9398556</ArticleId><ArticleId IdType="pubmed">36088825</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrey A.C., Qeadan F., A Middleton E., Pinchuk I.V., A Campbell R., Beswick E.J. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J. Leukoc. Biol. 2021;109:55&#x2013;66. doi: 10.1002/JLB.3COVA0820-410RRR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVA0820-410RRR</ArticleId><ArticleId IdType="pmc">PMC7902354</ArticleId><ArticleId IdType="pubmed">32930456</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlan A.N., Sutherland T.E., Marie C., Preissner S., Bradley B.T., Carpenter R.M., Sturek J.M., Ma J.Z., Moreau G.B., Donowitz J.R., et al. IL-13 is a driver of COVID-19 severity. JCI Insight. 2021;6:e150107. doi: 10.1172/jci.insight.150107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.150107</ArticleId><ArticleId IdType="pmc">PMC8410056</ArticleId><ArticleId IdType="pubmed">34185704</ArticleId></ArticleIdList></Reference><Reference><Citation>Orecchioni M., Ghosheh Y., Pramod A.B., Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS&#x2013;) vs. Alternatively Activated Macrophages. Front. Immunol. 2019;10:1084. doi: 10.3389/fimmu.2019.01084. Erratum in Front. Immunol. 2020, 11, 234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01084</ArticleId><ArticleId IdType="pmc">PMC6543837</ArticleId><ArticleId IdType="pubmed">31178859</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando M.R., Reyes J.L., Iannuzzi J., Leung G., McKay D.M. The Pro-Inflammatory Cytokine, Interleukin-6, Enhances the Polarization of Alternatively Activated Macrophages. PLoS ONE. 2014;9:e94188. doi: 10.1371/journal.pone.0094188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094188</ArticleId><ArticleId IdType="pmc">PMC3988054</ArticleId><ArticleId IdType="pubmed">24736635</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip K., Mills W.T., Davies J., Luo F., Molina J.G., Sinha N., Guha A., Eltzschig H.K., Blackburn M.R., Chen N.-Y., et al. HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2017;31:4745&#x2013;4758. doi: 10.1096/fj.201700219R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700219R</ArticleId><ArticleId IdType="pmc">PMC5636704</ArticleId><ArticleId IdType="pubmed">28701304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonser L.R., Eckalbar W.L., Rodriguez L., Shen J., Koh K.D., Ghias K., Zlock L.T., Christenson S., Woodruff P.G., Finkbeiner W.E., et al. The Type 2 Asthma Mediator IL-13 Inhibits Severe Acute Respiratory Syndrome Coronavirus 2 Infection of Bronchial Epithelium. Am. J. Respir. Cell Mol. Biol. 2022;66:391&#x2013;401. doi: 10.1165/rcmb.2021-0364OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0364OC</ArticleId><ArticleId IdType="pmc">PMC8990122</ArticleId><ArticleId IdType="pubmed">34982656</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A., Meng W., Liu Z., Hasib M., Galloway H., da Silva S.R., Chen L., Sica G.L., Paniz-Mondolfi A., Bryce C., et al. Molecular and immune signatures, and pathological trajectories of fatal COVID-19 lungs defined by in situ spatial single-cell transcriptome analysis. J. Med. Virol. 2023;95:e29009. doi: 10.1002/jmv.29009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29009</ArticleId><ArticleId IdType="pmc">PMC10442191</ArticleId><ArticleId IdType="pubmed">37563850</ArticleId></ArticleIdList></Reference><Reference><Citation>Londres H.D., Armada J.J., Mart&#xed;nez A.H., Cuza A.A.A., S&#xe1;nchez Y.H., Rodr&#xed;guez A.G., Figueroa S.S., Gregorich E.M.L., Lahera M.L.T., Peire F.G., et al. Blocking EGFR with nimotuzumab: A novel strategy for COVID-19 treatment. Immunotherapy. 2022;14:521&#x2013;530. doi: 10.2217/imt-2022-0027.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2022-0027</ArticleId><ArticleId IdType="pmc">PMC8936166</ArticleId><ArticleId IdType="pubmed">35306855</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot A., Bayliffe A., O&#x2019;Kane C.M., Wright T., Serone A., Bareille P.J., Brown V., Hamid U.I., Chen Y., Wilson R., et al. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax. 2018;73:723&#x2013;730. doi: 10.1136/thoraxjnl-2017-210305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2017-210305</ArticleId><ArticleId IdType="pmc">PMC6204954</ArticleId><ArticleId IdType="pubmed">29382797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouroupis D., Lanzoni G., Linetsky E., Cayetano S.M., Metalonis S.W., Le&#xf1;ero C., Stone L.D., Ruiz P., Correa D., Ricordi C. Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4435&#x2013;4438. doi: 10.26355/EURREV_202106_26156.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/EURREV_202106_26156</ArticleId><ArticleId IdType="pubmed">34227081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Shan F., Zhang Y., Jiang L., Cheng Z. Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13:2483&#x2013;2494. doi: 10.2147/COPD.S167192.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S167192</ArticleId><ArticleId IdType="pmc">PMC6108328</ArticleId><ArticleId IdType="pubmed">30154651</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacha O., Sallman M.A., Evans S.E. COVID-19: A case for inhibiting IL-17? Nat. Rev. Immunol. 2020;20:345&#x2013;346. doi: 10.1038/s41577-020-0328-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0328-z</ArticleId><ArticleId IdType="pmc">PMC7194244</ArticleId><ArticleId IdType="pubmed">32358580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Ao J., Ai C., Chen X. Molecular and functional identification of three interleukin-17A/F (IL-17A/F) homologues in large yellow croaker (Larimichthys crocea) Dev. Comp. Immunol. 2016;55:221&#x2013;232. doi: 10.1016/j.dci.2015.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dci.2015.09.010</ArticleId><ArticleId IdType="pubmed">26429410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono M., Miyashita K., Hirama R., Oshima Y., Takeda K., Mochizuka Y., Tsutsumi A., Miwa H., Miki Y., Hashimoto D., et al. Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease. Respir. Med. 2021;186:106534. doi: 10.1016/j.rmed.2021.106534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106534</ArticleId><ArticleId IdType="pubmed">34260978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang D., Wang L., Wang S., Roden A.C., Zhao H., Li X., Prakash Y.S., Matteson E.L., Tschumperlin D.J., et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am. J. Physiol. Cell. Mol. Physiol. 2019;316:L487&#x2013;L497. doi: 10.1152/ajplung.00301.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00301.2018</ArticleId><ArticleId IdType="pubmed">30604628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Liu Y., Zou J.-F., Cheng Z.-S. Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-&#x3b2;1 mediated Smad2/3 and ERK1/2 activation. PLoS ONE. 2017;12:e0183972. doi: 10.1371/journal.pone.0183972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0183972</ArticleId><ArticleId IdType="pmc">PMC5584923</ArticleId><ArticleId IdType="pubmed">28873461</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo L.D.N., Righetti R.F., Arist&#xf3;teles L.R.D.C.R.B., Dos Santos T.M., de Souza F.C.R., Fukuzaki S., Cruz M.M., Alonso-Vale M.I.C., Saraiva-Romanholo B.M., Prado C.M., et al. Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS. Front. Immunol. 2018;8:1835. doi: 10.3389/fimmu.2017.01835.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01835</ArticleId><ArticleId IdType="pmc">PMC5760512</ArticleId><ArticleId IdType="pubmed">29379497</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatt S., Baeten D., Baker T., Griffiths M., Ionescu L., Lawson A.D.G., Maroof A., Oliver R., Popa S., Strimenopoulou F., et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann. Rheum. Dis. 2018;77:523&#x2013;532. doi: 10.1136/annrheumdis-2017-212127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212127</ArticleId><ArticleId IdType="pmc">PMC5890624</ArticleId><ArticleId IdType="pubmed">29275332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazancioglu S., Yilmaz F.M., Bastug A., Ozbay B.O., Aydos O., Y&#xfc;cel &#xc7;., Bodur H., Yilmaz G. Assessment of Galectin-1, Galectin-3, and Prostaglandin E2 Levels in Patients with COVID-19. Jpn. J. Infect. Dis. 2021;74:530&#x2013;536. doi: 10.7883/yoken.JJID.2021.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2021.020</ArticleId><ArticleId IdType="pubmed">33790073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathiriya J.J., Nakra N., Nixon J., Patel P.S., Vaghasiya V., Alhassani A., Tian Z., Allen-Gipson D., Dav&#xe9; V. Galectin-1 inhibition attenuates profibrotic signaling in hypoxia-induced pulmonary fibrosis. Cell Death Discov. 2017;3:17010. doi: 10.1038/cddiscovery.2017.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddiscovery.2017.10</ArticleId><ArticleId IdType="pmc">PMC5385413</ArticleId><ArticleId IdType="pubmed">28417017</ArticleId></ArticleIdList></Reference><Reference><Citation>Caniglia J.L., Guda M.R., Asuthkar S., Tsung A.J., Velpula K.K. A potential role for Galectin-3 inhibitors in the treatment of COVID-19. PeerJ. 2020;8:e9392. doi: 10.7717/peerj.9392.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9392</ArticleId><ArticleId IdType="pmc">PMC7301894</ArticleId><ArticleId IdType="pubmed">32587806</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia W., Wang Z., Gao C., Wu J., Wu Q. Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis. Cell Death Dis. 2021;12:327. doi: 10.1038/s41419-021-03603-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03603-0</ArticleId><ArticleId IdType="pmc">PMC7998015</ArticleId><ArticleId IdType="pubmed">33771973</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguillos M.A., Svensson M., Schulte T., Boza-Serrano A., Garcia-Quintanilla A., Kavanagh E., Santiago M., Viceconte N., Oliva-Martin M.J., Osman A.M., et al. Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. Cell Rep. 2015;10:1626&#x2013;1638. doi: 10.1016/j.celrep.2015.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.012</ArticleId><ArticleId IdType="pubmed">25753426</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Revilla J., Deierborg T., Venero J.L., Boza-Serrano A. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front. Immunol. 2020;11:2069. doi: 10.3389/fimmu.2020.02069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02069</ArticleId><ArticleId IdType="pmc">PMC7461806</ArticleId><ArticleId IdType="pubmed">32973815</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman M., Pardo A. The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. Cell. Signal. 2020;66:109482. doi: 10.1016/j.cellsig.2019.109482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2019.109482</ArticleId><ArticleId IdType="pubmed">31760172</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie B., Korfei M., Henneke I., Sibinska Z., Tian X., Hezel S., Dilai S., Wasnick R., Schneider B., Wilhelm J., et al. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir. Res. 2015;16:83. doi: 10.1186/s12931-015-0242-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-015-0242-2</ArticleId><ArticleId IdType="pmc">PMC4495640</ArticleId><ArticleId IdType="pubmed">26138239</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant R.A., Grant R.A., Morales-Nebreda L., Morales-Nebreda L., Markov N.S., Markov N.S., Swaminathan S., Swaminathan S., Querrey M., Querrey M., et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590:635&#x2013;641. doi: 10.1038/s41586-020-03148-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03148-w</ArticleId><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Budinger G.S., Misharin A.V., Ridge K.M., Singer B.D., Wunderink R.G. Distinctive features of severe SARS-CoV-2 pneumonia. J. Clin. Investig. 2021;131:e149412. doi: 10.1172/JCI149412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149412</ArticleId><ArticleId IdType="pmc">PMC8279580</ArticleId><ArticleId IdType="pubmed">34263736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacher P., Rosati E., Esser D., Martini G.R., Saggau C., Schiminsky E., Dargvainiene J., Schr&#xf6;der I., Wieters I., Khodamoradi Y., et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity. 2020;53:1258&#x2013;1271.e5. doi: 10.1016/j.immuni.2020.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7689350</ArticleId><ArticleId IdType="pubmed">33296686</ArticleId></ArticleIdList></Reference><Reference><Citation>Medici D., Potenta S., Kalluri R. Transforming growth factor-&#x3b2;2 promotes Snail-mediated endothelial&#x2013;mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem. J. 2011;437:515&#x2013;520. doi: 10.1042/BJ20101500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20101500</ArticleId><ArticleId IdType="pmc">PMC4457510</ArticleId><ArticleId IdType="pubmed">21585337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto N., Phan S.H., Imaizumi K., Matsuo M., Nakashima H., Kawabe T., Shimokata K., Hasegawa Y. Endothelial&#x2013;Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 2010;43:161&#x2013;172. doi: 10.1165/rcmb.2009-0031OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2009-0031OC</ArticleId><ArticleId IdType="pmc">PMC2937229</ArticleId><ArticleId IdType="pubmed">19767450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., Chandraker A., Yuan X., Pu W.T., Roberts A.B., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007;13:952&#x2013;961. doi: 10.1038/nm1613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1613</ArticleId><ArticleId IdType="pubmed">17660828</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisagbonhi O., Rai M., Ryzhov S., Atria N., Feoktistov I., Hatzopoulos A.K. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis. Model. Mech. 2011;4:469&#x2013;483. doi: 10.1242/dmm.006510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.006510</ArticleId><ArticleId IdType="pmc">PMC3124051</ArticleId><ArticleId IdType="pubmed">21324930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaikwad A.V., Lu W., Dey S., Bhattarai P., Haug G., Larby J., Chia C., Jaffar J., Westall G., Singhera G.K., et al. Endothelial-to-mesenchymal transition: A precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2023;9:00487&#x2013;2022. doi: 10.1183/23120541.00487-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00487-2022</ArticleId><ArticleId IdType="pmc">PMC10107070</ArticleId><ArticleId IdType="pubmed">37077555</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;agnillo F., Walters K.-A., Xiao Y., Sheng Z.-M., Scherler K., Park J., Gygli S., Rosas L.A., Sadtler K., Kalish H., et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 2021;13:eabj7790. doi: 10.1126/scitranslmed.abj7790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj7790</ArticleId><ArticleId IdType="pmc">PMC11000440</ArticleId><ArticleId IdType="pubmed">34648357</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey T.M., Ziegler C.G.K., Heimberg G., Normand R., Yang Y., Segerstolpe &#xc5;., Abbondanza D., Fleming S.J., Subramanian A., Montoro D.T., et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595:107&#x2013;113. doi: 10.1038/s41586-021-03570-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03570-8</ArticleId><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandolfi L., Bozzini S., Frangipane V., Percivalle E., De Luigi A., Violatto M.B., Lopez G., Gabanti E., Carsana L., D&#x2019;amato M., et al. Neutrophil Extracellular Traps Induce the Epithelial-Mesenchymal Transition: Implications in Post-COVID-19 Fibrosis. Front. Immunol. 2021;12:663303. doi: 10.3389/fimmu.2021.663303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.663303</ArticleId><ArticleId IdType="pmc">PMC8236949</ArticleId><ArticleId IdType="pubmed">34194429</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms J.C., Biermann J., Huang H., Wang Y., Nair A., Tagore S., Katsyv I., Rendeiro A.F., Amin A.D., Schapiro D., et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595:114&#x2013;119. doi: 10.1038/s41586-021-03569-1. Erratum in Nature 2021, 598, E2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03569-1</ArticleId><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Reed A., Desai S.R., Devaraj A., Faiez T.S., Laverty S., Kanwal A., Esneau C., Liu M.K., Kamal F., et al. A persistent neutrophil-associated immune signature characterizes post&#x2013;COVID-19 pulmonary sequelae. Sci. Transl. Med. 2022;14:eabo5795. doi: 10.1126/scitranslmed.abo5795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5795</ArticleId><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby I.A., Hewitson T.D. Fibroblast differentiation in wound healing and fibrosis. Int. Rev. Cytol. 2007;257:143&#x2013;179. doi: 10.1016/S0074-7696(07)57004-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0074-7696(07)57004-X</ArticleId><ArticleId IdType="pubmed">17280897</ArticleId></ArticleIdList></Reference><Reference><Citation>de Paula C.B.V., Nagashima S., Liberalesso V., Collete M., da Silva F.P.G., Oricil A.G.G., Barbosa G.S., da Silva G.V.C., Wiedmer D.B., Dezid&#xe9;rio F.d.S., et al. COVID-19: Immunohistochemical Analysis of TGF-&#x3b2; Signaling Pathways in Pulmonary Fibrosis. Int. J. Mol. Sci. 2021;23:168. doi: 10.3390/ijms23010168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010168</ArticleId><ArticleId IdType="pmc">PMC8745764</ArticleId><ArticleId IdType="pubmed">35008594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirbhate E., Pandey J., Patel V.K., Kamal M., Jawaid T., Gorain B., Kesharwani P., Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: A potential approach for therapeutic intervention. Pharmacol. Rep. 2021;73:1539&#x2013;1550. doi: 10.1007/s43440-021-00303-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00303-6</ArticleId><ArticleId IdType="pmc">PMC8236094</ArticleId><ArticleId IdType="pubmed">34176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Oatis D., Simon-Repolski E., Balta C., Mihu A., Pieretti G., Alfano R., Peluso L., Trotta M.C., D&#x2019;amico M., Hermenean A. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9. Int. J. Mol. Sci. 2022;23:8210. doi: 10.3390/ijms23158210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158210</ArticleId><ArticleId IdType="pmc">PMC9332679</ArticleId><ArticleId IdType="pubmed">35897786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Huang G., Wang Z., Qin H., Mo B., Wang C. Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts. Exp. Cell Res. 2018;363:291&#x2013;298. doi: 10.1016/j.yexcr.2018.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2018.01.019</ArticleId><ArticleId IdType="pubmed">29355493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukihara J., Kondoh Y. COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases. Respir. Investig. 2023;61:601&#x2013;617. doi: 10.1016/j.resinv.2023.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2023.05.007</ArticleId><ArticleId IdType="pmc">PMC10281233</ArticleId><ArticleId IdType="pubmed">37429073</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingberg F., Hinz B., White E.S. The myofibroblast matrix: Implications for tissue repair and fibrosis. J. Pathol. 2013;229:298&#x2013;309. doi: 10.1002/path.4104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4104</ArticleId><ArticleId IdType="pmc">PMC4005341</ArticleId><ArticleId IdType="pubmed">22996908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruglikov I.L., Scherer P.E. The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections. Obesity. 2020;28:1187&#x2013;1190. doi: 10.1002/oby.22856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22856</ArticleId><ArticleId IdType="pmc">PMC7267593</ArticleId><ArticleId IdType="pubmed">32339391</ArticleId></ArticleIdList></Reference><Reference><Citation>Youk J., Kim T., Evans K.V., Jeong Y.-I., Hur Y., Hong S.P., Kim J.H., Yi K., Kim S.Y., Na K.J., et al. Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. Cell Stem Cell. 2020;27:905&#x2013;919.e10. doi: 10.1016/j.stem.2020.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7577700</ArticleId><ArticleId IdType="pubmed">33142113</ArticleId></ArticleIdList></Reference><Reference><Citation>El Agha E., Moiseenko A., Kheirollahi V., De Langhe S., Crnkovic S., Kwapiszewska G., Szibor M., Kosanovic D., Schwind F., Schermuly R.T., et al. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. Cell Stem Cell. 2017;20:261&#x2013;273.e3. doi: 10.1016/j.stem.2016.10.004. Erratum in Cell Stem Cell 2017, 20, 571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.10.004</ArticleId><ArticleId IdType="pmc">PMC5291816</ArticleId><ArticleId IdType="pubmed">27867035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Yang L., Huang K. COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment. Diabetes Metab. Syndr. Obesity Targets Ther. 2020;13:4953&#x2013;4959. doi: 10.2147/DMSO.S285197.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DMSO.S285197</ArticleId><ArticleId IdType="pmc">PMC7753883</ArticleId><ArticleId IdType="pubmed">33363393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouri-Keshtkar M., Taghizadeh S., Farhadi A., Ezaddoustdar A., Vesali S., Hosseini R., Totonchi M., Kouhkan A., Chen C., Zhang J.-S., et al. Potential Impact of Diabetes and Obesity on Alveolar Type 2 (AT2)-Lipofibroblast (LIF) Interactions After COVID-19 Infection. Front. Cell Dev. Biol. 2021;9:676150. doi: 10.3389/fcell.2021.676150.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.676150</ArticleId><ArticleId IdType="pmc">PMC8295688</ArticleId><ArticleId IdType="pubmed">34307358</ArticleId></ArticleIdList></Reference><Reference><Citation>John A.E., Joseph C., Jenkins G., Tatler A.L. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol. Rev. 2021;302:228&#x2013;240. doi: 10.1111/imr.12977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12977</ArticleId><ArticleId IdType="pmc">PMC8237078</ArticleId><ArticleId IdType="pubmed">34028807</ArticleId></ArticleIdList></Reference><Reference><Citation>SEZG&#x130;N A.K. Lung fibrosis molecular mechanisms. Osman. J. Med. 2023;45:1005&#x2013;1010. doi: 10.20515/otd.1306315.</Citation><ArticleIdList><ArticleId IdType="doi">10.20515/otd.1306315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H., et al. Identification of Smad7, a TGF&#x3b2;-inducible antagonist of TGF-beta signalling. Nature. 1997;389:631&#x2013;635. doi: 10.1038/39369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/39369</ArticleId><ArticleId IdType="pubmed">9335507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi M., Aono Y., Sato S., Koyama K., Azuma M., Abe S., Kawano H., Kishi J., Toyoda Y., Okazaki H., et al. Blockade of platelet-derived growth factor receptor-beta, not receptor-alpha ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS ONE. 2018;13:e0209786. doi: 10.1371/journal.pone.0209786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209786</ArticleId><ArticleId IdType="pmc">PMC6312310</ArticleId><ArticleId IdType="pubmed">30596712</ArticleId></ArticleIdList></Reference><Reference><Citation>Moodley Y.P., Scaffidi A.K., Misso N.L., Keerthisingam C., McAnulty R.J., Laurent G.J., Mutsaers S.E., Thompson P.J., Knight D.A. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am. J. Pathol. 2003;163:345&#x2013;354. doi: 10.1016/S0002-9440(10)63658-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63658-9</ArticleId><ArticleId IdType="pmc">PMC1868172</ArticleId><ArticleId IdType="pubmed">12819039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B., Dong J., D&#x2019;agostino G., Viswanathan S., Widjaja A.A., Lim W.-W., Ko N.S.J., Tan J., Chothani S.P., Huang B., et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci. Transl. Med. 2019;11:eaaw1237. doi: 10.1126/scitranslmed.aaw1237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaw1237</ArticleId><ArticleId IdType="pubmed">31554736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholaminejhad M., Forouzesh M., Ebrahimi B., Mahdavi S.A., Mirtorabi S.D., Liaghat A., Monabati S.J., Hamza M.O., Hassanzadeh G. Formation and activity of NLRP3 inflammasome and histopathological changes in the lung of corpses with COVID-19. J. Mol. Histol. 2022;53:883&#x2013;890. doi: 10.1007/s10735-022-10101-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-022-10101-w</ArticleId><ArticleId IdType="pmc">PMC9470508</ArticleId><ArticleId IdType="pubmed">36100803</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) Chin. Med. J. 2020;133:1087&#x2013;1095. doi: 10.1097/CM9.0000000000000819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000819</ArticleId><ArticleId IdType="pmc">PMC7213636</ArticleId><ArticleId IdType="pubmed">32358325</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouqui P., Amrane S., Million M., Cortaredona S., Parola P., Lagier J.-C., Raoult D. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int. J. Infect. Dis. 2021;102:233&#x2013;238. doi: 10.1016/j.ijid.2020.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.067</ArticleId><ArticleId IdType="pmc">PMC7604151</ArticleId><ArticleId IdType="pubmed">33130200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatnagar S., Sirohiya P., Elavarasi A., Sagiraju H.R., Baruah M., Gupta N., Garg R., Paul S., Ratre B., Singh R., et al. Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? -A retrospective cohort study. Lung India. 2022;39:247&#x2013;253. doi: 10.4103/lungindia.lungindia_601_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/lungindia.lungindia_601_21</ArticleId><ArticleId IdType="pmc">PMC9200195</ArticleId><ArticleId IdType="pubmed">35488682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M., Liu W., Li X., Zhao P., Shereen M.A., Zhu C., Huang S., Liu S., Yu X., Yue M., et al. HIF-1&#x3b1; promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct. Target. Ther. 2021;6:308. doi: 10.1038/s41392-021-00726-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00726-w</ArticleId><ArticleId IdType="pmc">PMC8371950</ArticleId><ArticleId IdType="pubmed">34408131</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W., Pan L., Cheng Y., Wu X., Tang B., Zhu H., Zhang M., Zhang Y. Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK/ERK/S100A4 signalling pathway. Int. Immunopharmacol. 2022;113:109409. doi: 10.1016/j.intimp.2022.109409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109409</ArticleId><ArticleId IdType="pubmed">36461602</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F., et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect. 2020;9:1123&#x2013;1130. doi: 10.1080/22221751.2020.1770129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., Cheng L., Li J., Wang X., Wang F., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S., Wang W., Qin W., Cheng K., Coulup S., Chavez S., Jiang S., Raparia K., De Almeida L.M.V., Stehlik C., et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. J. Clin. Investig. 2018;3:98850. doi: 10.1172/jci.insight.98850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.98850</ArticleId><ArticleId IdType="pmc">PMC6124522</ArticleId><ArticleId IdType="pubmed">29997297</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovic S.S., Gajovic N., Jurisevic M., Jovanovic M., Jovicic B.P., Arsenijevic N., Mijailovic Z., Dolicanin Z., Jovanovic I. Galectin-1 as the new player in staging and prognosis of COVID-19. Sci. Rep. 2022;12:1272. doi: 10.1038/s41598-021-04602-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04602-z</ArticleId><ArticleId IdType="pmc">PMC8786829</ArticleId><ArticleId IdType="pubmed">35075140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozorgmehr N., Mashhouri S., Rosero E.P., Xu L., Shahbaz S., Sligl W., Osman M., Kutsogiannis D.J., MacIntyre E., O&#x2019;neil C.R., et al. Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection. mBio. 2021;12:e00384-21. doi: 10.1128/mBio.00384-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00384-21</ArticleId><ArticleId IdType="pmc">PMC8262904</ArticleId><ArticleId IdType="pubmed">33947753</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., Bouzidi M.S., Gala A., Deiter F., Billaud J.N., Yeung S.T., Dabral P., Jin J., Simmons G., Pillai S.K., et al. Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation in Airway Epithelial Cells. J. Mol. Cell Biol. 2023;15:mjad030. doi: 10.1101/2022.03.18.484956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.18.484956</ArticleId><ArticleId IdType="pmc">PMC10668544</ArticleId><ArticleId IdType="pubmed">37127426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Qu R., Junqueira C., Kaffe E., Mirza H., Zhao J., Brewer J.R., Han A., Steach H.R., Israelow B., et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606:585&#x2013;593. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Xu X., Jiang L., Dua K., Hansbro P.M., Liu G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir. Res. 2020;21:182. doi: 10.1186/s12931-020-01445-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01445-6</ArticleId><ArticleId IdType="pmc">PMC7359430</ArticleId><ArticleId IdType="pubmed">32664949</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris E.G., Pan X.S., Hocking D.C. Receptor-binding domain of SARS-CoV-2 is a functional &#x3b1;v-integrin agonist. J. Biol. Chem. 2023;299:102922. doi: 10.1016/j.jbc.2023.102922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.102922</ArticleId><ArticleId IdType="pmc">PMC9846890</ArticleId><ArticleId IdType="pubmed">36669646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.-Y., Ju C.-Y., Wu L.-Z., Yan H., Hong W.-B., Chen H.-Z., Yang P.-B., Wang B.-R., Gou T., Chen X.-Y., et al. Therapeutic potency of compound RMY-205 for pulmonary fibrosis induced by SARS-CoV-2 nucleocapsid protein. Cell Chem. Biol. 2023;30:261&#x2013;277.e8. doi: 10.1016/j.chembiol.2023.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2023.02.004</ArticleId><ArticleId IdType="pmc">PMC9990178</ArticleId><ArticleId IdType="pubmed">36889311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinz B., Celetta G., Tomasek J.J., Gabbiani G., Chaponnier C. Alpha-Smooth Muscle Actin Expression Upregulates Fibroblast Contractile Activity. Mol. Biol. Cell. 2001;12:2730&#x2013;2741. doi: 10.1091/mbc.12.9.2730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.12.9.2730</ArticleId><ArticleId IdType="pmc">PMC59708</ArticleId><ArticleId IdType="pubmed">11553712</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen J.T., A Spiteri M. Growth factors in idiopathic pulmonary fibrosis: Relative roles. Respir. Res. 2001;3:13. doi: 10.1186/rr162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/rr162</ArticleId><ArticleId IdType="pmc">PMC64811</ArticleId><ArticleId IdType="pubmed">11806848</ArticleId></ArticleIdList></Reference><Reference><Citation>Krafts K.P. Tissue repair. Organogenesis. 2010;6:225&#x2013;233. doi: 10.4161/org.6.4.12555.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/org.6.4.12555</ArticleId><ArticleId IdType="pmc">PMC3055648</ArticleId><ArticleId IdType="pubmed">21220961</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Cooley M.A., Jarnicki A.G., Borghui T., Nair P.M., Tjin G., Hsu A.C., Haw T.J., Fricker M., Harrison C.L., et al. Fibulin-1c regulates transforming growth factor-&#x3b2; activation in pulmonary tissue fibrosis. JCI Insight. 2019;4:e124529. doi: 10.1172/jci.insight.124529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.124529</ArticleId><ArticleId IdType="pmc">PMC6777837</ArticleId><ArticleId IdType="pubmed">31343988</ArticleId></ArticleIdList></Reference><Reference><Citation>Argraves W.S., Tran H., Burgess W.H., Dickerson K. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. Pt 2J. Cell Biol. 1990;111:3155&#x2013;3164. doi: 10.1083/jcb.111.6.3155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.111.6.3155</ArticleId><ArticleId IdType="pmc">PMC2116371</ArticleId><ArticleId IdType="pubmed">2269669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanni S.E., Fabro A.T., de Albuquerque A., Ferreira E.V.M., Verrastro C.G.Y., Sawamura M.V.Y., Ribeiro S.M., Baldi B.G. Pulmonary fibrosis secondary to COVID-19: A narrative review. Expert Rev. Respir. Med. 2021;15:791&#x2013;803. doi: 10.1080/17476348.2021.1916472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2021.1916472</ArticleId><ArticleId IdType="pubmed">33902377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridi G.d.P., Tanni S.E., Baldi B.G. Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We? Arch. Bronconeumol. 2022;59:69&#x2013;70. doi: 10.1016/j.arbres.2022.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2022.07.014</ArticleId><ArticleId IdType="pmc">PMC9395235</ArticleId><ArticleId IdType="pubmed">36041958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiner-Vives E., Cordovilla-P&#xe9;rez R., de la Rosa-Carrillo D., Garc&#xed;a-Clemente M., Izquierdo-Alonso J.L., Otero-Candelera R., Llano L.P.-D., Sellares-Torres J., de Granda-Orive J.I. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Arch. Bronconeumol. 2022;58((Suppl. 1)):39&#x2013;50. doi: 10.1016/j.arbres.2022.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2022.03.011</ArticleId><ArticleId IdType="pmc">PMC9012323</ArticleId><ArticleId IdType="pubmed">35501222</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi B.G., Tanni S.E. Pulmonary fibrosis and follow-up of COVID-19 survivors: An urgent need for clarification. J. Bras. de Pneumol. 2021;47:e20210213. doi: 10.36416/1806-3756/e20210213.</Citation><ArticleIdList><ArticleId IdType="doi">10.36416/1806-3756/e20210213</ArticleId><ArticleId IdType="pmc">PMC8979668</ArticleId><ArticleId IdType="pubmed">34495179</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvisi M., Ferrozzi F., Balzarini L., Mancini C., Ramponi S., Uccelli M. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. Int. J. Infect. Dis. 2020;99:485&#x2013;488. doi: 10.1016/j.ijid.2020.08.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.054</ArticleId><ArticleId IdType="pmc">PMC7443096</ArticleId><ArticleId IdType="pubmed">32841688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z.-J., Xu J., Yin J.-M., Li L., Hou W., Zhang L.-L., Zhou Z., Yu Y.-Z., Li H.-J., Feng Y.-M., et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. Front. Immunol. 2020;11:585647. doi: 10.3389/fimmu.2020.585647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.585647</ArticleId><ArticleId IdType="pmc">PMC7550399</ArticleId><ArticleId IdType="pubmed">33133104</ArticleId></ArticleIdList></Reference><Reference><Citation>Siekacz K., Kumor-Kisielewska A., Mi&#x142;kowska-Dymanowska J., Pietrusi&#x144;ska M., Bartczak K., Majewski S., Sta&#x144;czyk A., Piotrowski W.J., Bia&#x142;as A.J. Oxidative Biomarkers Associated with the Pulmonary Manifestation of Post-COVID-19 Complications. J. Clin. Med. 2023;12:4253. doi: 10.3390/jcm12134253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12134253</ArticleId><ArticleId IdType="pmc">PMC10342941</ArticleId><ArticleId IdType="pubmed">37445288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Ben&#xed;tez N.E., Parotto M., Post M., Han B., Spieth P.M., Cheng W.-E., Valladares F., Villar J., Liu M., Sato M., et al. Mechanical stress induces lung fibrosis by epithelial&#x2013;mesenchymal transition*. Crit. Care Med. 2012;40:510&#x2013;517. doi: 10.1097/CCM.0b013e31822f09d7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31822f09d7</ArticleId><ArticleId IdType="pmc">PMC5061566</ArticleId><ArticleId IdType="pubmed">21926573</ArticleId></ArticleIdList></Reference><Reference><Citation>Froese A.R., Shimbori C., Bellaye P.-S., Inman M., Obex S., Fatima S., Jenkins G., Gauldie J., Ask K., Kolb M. Stretch-induced Activation of Transforming Growth Factor-&#x3b2;1 in Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2016;194:84&#x2013;96. doi: 10.1164/rccm.201508-1638OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201508-1638OC</ArticleId><ArticleId IdType="pubmed">26771871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Shi J., He Z., L&#xfc; Y., Xu Q., Ye C., Chen S., Tang B., Yin K., Lu Y., et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020;12:6037&#x2013;6048. doi: 10.18632/aging.102999.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102999</ArticleId><ArticleId IdType="pmc">PMC7185104</ArticleId><ArticleId IdType="pubmed">32275643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar M., Barbu E.C., Chitu C.E., Anghel A.-M., Niculae C.-M., Manea E.-D., Damalan A.-C., Bel A.-A., Patrascu R.-E., Hristea A., et al. Mortality Predictors in Severe SARS-CoV-2 Infection. Medicina. 2022;58:945. doi: 10.3390/medicina58070945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58070945</ArticleId><ArticleId IdType="pmc">PMC9324408</ArticleId><ArticleId IdType="pubmed">35888664</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3. Erratum in Lancet 2020, 395, 1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Shen C., Wang L., Majumder S., Zhang D., Deen J., Li Y., Qing L., Zhang Y., Chen C., et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: A cohort study. Respir. Res. 2021;22:203. doi: 10.1186/s12931-021-01798-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01798-6</ArticleId><ArticleId IdType="pmc">PMC8267229</ArticleId><ArticleId IdType="pubmed">34243776</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony T., Acharya K.V., Unnikrishnan B., Keerthi N. A silent march-Post covid fibrosis in asymptomatics&#x2014;A cause for concern? Indian J. Tuberc. 2023;70:249&#x2013;252. doi: 10.1016/j.ijtb.2022.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2022.05.004</ArticleId><ArticleId IdType="pmc">PMC9131542</ArticleId><ArticleId IdType="pubmed">37100584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Plata R., Higuera-Iglesias A.-L., Torres-Esp&#xed;ndola L.M., Aquino-G&#xe1;lvez A., Cruz R.V., Camarena &#xc1;., Alderete J.C., Garc&#xed;a J.R., Alvarado-V&#xe1;squez N., Brise&#xf1;o D.M., et al. Risk of Pulmonary Fibrosis and Persistent Symptoms Post-COVID-19 in a Cohort of Outpatient Health Workers. Viruses. 2022;14:1843. doi: 10.3390/v14091843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091843</ArticleId><ArticleId IdType="pmc">PMC9504101</ArticleId><ArticleId IdType="pubmed">36146648</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W., Wu Q., Chen Z., Xiong Z., Wang K., Tian J., Zhang S. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J. Infect. 2020;82:e5&#x2013;e7. doi: 10.1016/j.jinf.2020.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.09.027</ArticleId><ArticleId IdType="pmc">PMC7521372</ArticleId><ArticleId IdType="pubmed">32998036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimilli S., Schmidt E., Damratoski B.E., Prasad G.L. Role of Oxidative Stress in the Suppression of Immune Responses in Peripheral Blood Mononuclear Cells Exposed to Combustible Tobacco Product Preparation. Inflammation. 2017;40:1622&#x2013;1630. doi: 10.1007/s10753-017-0602-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0602-9</ArticleId><ArticleId IdType="pmc">PMC5587635</ArticleId><ArticleId IdType="pubmed">28577134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellou V., Belbasis L., Evangelou E. Tobacco Smoking and Risk for Pulmonary Fibrosis: A Prospective Cohort Study From the UK Biobank. Chest. 2021;160:983&#x2013;993. doi: 10.1016/j.chest.2021.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.04.035</ArticleId><ArticleId IdType="pubmed">33905677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Tao Z.-W., Wang L., Yuan M.-L., Liu K., Zhou L., Wei S., Deng Y., Liu J., Liu H.-G., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. 2020;133:1032&#x2013;1038. doi: 10.1097/CM9.0000000000000775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000775</ArticleId><ArticleId IdType="pmc">PMC7147279</ArticleId><ArticleId IdType="pubmed">32118640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sueblinvong V., Kerchberger V.E., Saghafi R., Mills S.T., Fan X., Guidot D.M. Chronic Alcohol Ingestion Primes the Lung for Bleomycin-Induced Fibrosis in Mice. Alcohol. Clin. Exp. Res. 2014;38:336&#x2013;343. doi: 10.1111/acer.12232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acer.12232</ArticleId><ArticleId IdType="pmc">PMC3869877</ArticleId><ArticleId IdType="pubmed">24033682</ArticleId></ArticleIdList></Reference><Reference><Citation>Iavarone M., D&#x2019;Ambrosio R., Soria A., Triolo M., Pugliese N., Del Poggio P., Perricone G., Massironi S., Spinetti A., Buscarini E., et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J. Hepatol. 2020;73:1063&#x2013;1071. doi: 10.1016/j.jhep.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7280108</ArticleId><ArticleId IdType="pubmed">32526252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>